In one of the largest transactions in the history of the pharma CDMO space, JLL Partners will take Patheon private and merge it with DSM Pharmaceutical Products (DPP). The total transaction cost will be nearly $2.6 billion and will result in a new company (“NewCo”) with approximately $2.0 billion in pro forma annual revenues. JLL will own 51% of NewCo and Royal DSM will own 49%. JLL will put $489 million into NewCo and Royal DSM will receive a seller note of $200 million for DPP, va...